WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell® Wearable Pain Relief Technology™ will be featured at the Western Foot & Ankle Conference to be held June 23-26 in Anaheim, CA.
“According to a survey by the American Academy of Podiatric Medicine, 77% of American adults suffer from foot pain,” says Frank McGillin, Senior Vice President and General Manager, Consumer of NeuroMetrix. “We are excited to share new research on the role that Quell's innovative technology can play in managing chronic pain. During the event we will showcase the newest version of the Quell technology, including the smartphone app for iOS and Android that helps users track their therapy and sleep.”
Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. Quell was recently awarded the Innovation Award at SXSW for best Wearable Technology. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.